Authors : Renu Sharma; Ankit Goel; Rahul Kaushik; Kapil Yadav; Hareem Fatima; Rajan Chauhan; Shaivi Parashar

Volume/Issue : Volume 10 - 2025, Issue 7 - July

Google Scholar : https://tinyurl.com/2pszyau8

Scribd : https://tinyurl.com/3jfaner6

DOI : https://doi.org/10.38124/ijisrt/25jul1619

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Epilepsy is a prevalent neurological condition affecting millions of people worldwide, with significant social and economic burdens. Despite the availability of various antiepileptic drugs (AEDs), many patients continue to experience uncontrolled seizures or adverse effects, highlighting the need for novel therapeutic agents. Heterocyclic compounds, especially five-membered rings like pyrazoline, have gained attention in drug discovery due to their diverse pharmacological activities. Pyrazoline, characterized by a dihydropyrazole ring, exhibits promising physiological properties relevant to the CNS. This review explores epilepsy’s pathophysiology and common mechanisms of existing AEDs, including modulation of ion channels and neurotransmitter balance. Pyrazoline derivatives demonstrate broad- spectrum activity and significant antiepileptic potential by targeting GABAergic and glutamatergic systems. Several studies report effective pyrazoline-based compounds with improved safety and efficacy profiles. This review includes proposed mechanisms, reaction schemes for synthesis, and a summary of reported pyrazoline derivatives as potential antiepileptic agents, reinforcing their role in future drug development.

Keywords : Pyrazoline, Heterocyclic Compound, Epilepsy, AED.

References :

1. Leonardi, M., & Ustun, T. B. The Global Burden of Epilepsy. Epilepsia, 43, 21-25. https://doi.org/10.1046/j.1528-1157.43.s.6.11.x
2. Beghi E. The epidemiology of epilepsy. Neuroepidemiology. 2020 Dec 18; 54(2):185-91.
3. Abstracts from the 19th International Epilepsy Congress, 1991, Rio de Janeiro, Brazil. Epilepsia 1991; 32(suppl 3).
4. Abstracts from the 20th International Epilepsy Congress, 1993, Oslo, Norway. Epilepsia 1993; 34(suppl 3).
5. Abstracts from the 21st International Epilepsy Congress, 1995, Sydney, Australia. Epilepsia 1995; 36(suppl 3).
6. Abstracts from the 22nd International Epilepsy Congress, 1997, Dublin, Ireland. Epilepsia 1997; 38(suppl 3).
7. Abstracts from the 23rd International Epilepsy Congress, 1999, Prague, Czech Republic. Epilepsia 1999; 4O (suppl 2).
8. World Health Organization. Progress towards health for all: third monitoring report. World Health Stat Q 1995; 48: 174-307.
9. Chindo BA, Adzu B, Gamaniel KS. Antiepileptic drug targets: an update on ion channels. InEpileptology-The Modern State of Science 2016 Oct 12. IntechOpen.
10. Łukawski K, Gryta P, Łuszczki J, Czuczwar SJ. Exploring the latest avenues for antiepileptic drug discovery and development. Expert opinion on drug discovery. 2016 Apr 2; 11(4):369-82.
11. Arora P, Arora V, Lamba HS, Wadhwa D. Importance of heterocyclic chemistry: A review. International Journal of Pharmaceutical Sciences and Research. 2012 Sep 1; 3(9):2947.
12. Taylor AP, Robinson RP, Fobian YM, Blakemore DC, Jones LH, Fadeyi O. Modern advances in heterocyclic chemistry in drug discovery. Organic & biomolecular chemistry. 2016; 14(28):6611-37.
13. Nusrat BA and Rabiul I: Cytotoxicity study of pyrazole derivatives. Bangladesh Journalof Pharmacology 2007; 2: 81-87. 3.
14. Rahman A and Siddiqui AA: Pyrazoline derivative: A Worthy Insight into the recent advances and potential pharmacological activities. International Journal of Pharmaceutical Sciences and Drug Research 2010; 2(3): 165-75.
15. Eisinger J, Boens N and Flores J: Fluorescence polarization study of human erythrocyte membranes with 1-phenyl-3-(2-naphthyl)-2- pyrazoline as orientational probe. Biochimcaet Biophysica Acta 1981; 646: 334-43.
16. Li JF, Guan B, Li DX and Dong C: Study on the fluorescence properties of a new intramolecular charge transfer compound 1,5- diphenyl-3-(N-ethylcarbazole-3- yl)-2-pyrazoline. Spectrochimica Acta Part A: Molecular and biomolecular Spectroscopy 2007; 68: 404-08.
17. Bai G, Li J, Li D, Dong C, Han X and Lin P: Synthesis and spectrum characteristic of four new organic fluorescent dyes of pyrazoline compounds. Dyesand Pigments 2007; 75: 93-98.
18. Lu Z, Jiang Q, Zhu W, Xie M, Hou Y, Chen X and Wang Z: Novel pyrazoline derivative used as light emitter in blue organic electroluminescent devices. Synthetic Metals 2000; 111: 465-68.
19. Evans NA, Rivett DE and Wilshire JFK: The chemical and photochemical properties of some 1, 3-diphenyl-2- pyrazolines. Australian Journal of Chemistry 2005; 27: 2267-74.
20. ElShora AI: Crystal and molecular structure of 3- hydrazino-1-hydrazinothio-carbonyl pyrazoline (TNT3). Egyptian Journal of Science 2000; 23: 251-54.
21. Li JT, Zhang XH and Lin ZP: An improved synthesis of 1, 3, 5-triaryl-2-pyrazolines in acetic acid aqueous solution under ultrasound irradiation. Beilstein Journal of Organic Chemistry 2007; 3: 1860-97.
22. Kelekci NG, Koyunoglu S, Yabanoglu S, Yelekci K, Ozgen O, Ucar G, Erol K, Kendi E and Yesilada A: New pyrazoline bearing 4-(3H)-quinazolinone inhibitors of monoamine oxidase: Synthesis,biological evaluation and structural determinants of MAO-A and MAO-B selectivity. Bioorganic and Medicinal Chemistry 2008; 22: 23-25.
23. Havrylyuk D, Zimenkovsky B, Vasylenko O, Zaprutko L, Gzella A and Lesyk R: Synthesis of novel thiazolonebased compounds containing pyrazoline moiety and evaluation of their anticancer activity. European Journal of Medicinal Chemistry 2008; 42: 1-9.
24. Sobhia HR, Yaminib Y, Esrafili A and Adiba M: Extraction and determination of 2-pyrazoline derivatives using liquid phase microextraction based on solidification of floating organic drop. Journal of Pharmaceutical and Biomedical Analysis 2008; 45: 316-20.
25. Gosselin F, O’Shea PD, Webster RA, Reamer RA, Tillyer RD and Grabowski EJJ: Highly regioselective synthesis of 1-Aryl-3,4,5-substotuted pyrazoles. Synlett 2006; 3267-70.
26. Marti BS, Ramon BM, Jordi LT. One-pot preparation of cinchonidine salt of (4S, 5S)-5-(4-chlorophenyl)-1-(2, 4- dichlorophenyl)-4-methyl-4, 5-dihydro1Hpyrazole-3-carboxylic acid. Eur Pat Appl. EP2314578A120110427; 2011
27. Yoo JU, Lee DW, Choi JG, et al. Preparation of 3, 4-diphenyl-4, 5-dihydropyrazole-1-carboxylic acid hydrazide compounds as cannabinoid 1 (CB1) modulators. Repub Korean Kongkae Taeho Kongbo
28. Yusuf M, Solanki I. Synthesis and antimicrobial studies of furyl based new bispyrazolines linked via aliphatic chains. J Saudi Chem Soc 2017; 21:251-61.
29. Asad M, Arshad MN, Khan SA, Ataualpa MO, Braga AC. Cyclization of chalcones into N-propionyl pyrazolines for their single-crystal X-ray, computational and antibacterial studies. J Mol Struct 2020; 120:127-6.
30. Edrees MM, Melha SA, Saad AM, Kheder NA, Gomha SM, Muhammad ZA. Eco-friendly synthesis, characterization and biological evaluation of some novel pyrazolines containing thiazole moiety as potential anticancer and antimicrobial agents. Molecules. 2018 Nov 14; 23(11):2970.
31. Barsoum FF, Girgis AS. Facile synthesis of bis (4, 5-dihydro-1H-pyrazole-1- carboxamides) and their thio-analogues of potential PGE (2) inhibitory properties. Eur J Med Chem 2009; 44:2172-7
32. Havrylyuk D, Zimenkovsky B, Vasylenko O, Zaprutko L, Gzella A and Lesyk R: Synthesis of novel thiazolonebased compoundscontaining pyrazoline moiety and evaluation of their anticancer activity. Europian Journal of Medicinal Chemistry 2008; 42: 1-9.
33. AliMA, Yar MS, Kumar M and Pandian GS: Synthesis and antitubercular activity of substituted novel pyrazoline derivatives. Natural Product Research 2007; 21: 575-79.
34. Svechkarev DA, Bukatich IV and Doroshenko AO: New 1, 3, 5 – triphenyl - 2 - pyrazoline-containing 3-hydroxychromones as highly solvatofluoro chromicratiometric polarity probes. J of Phytochemistry and Photobiology A: Chemistry 2008; 200: 426-31
35. Rao BM, Ramesh S, Bardalai D, Rahman H and Shaik HA. Synthesis, characterization and evaluation of antiepileptic activity of four new 2-pyrazoline derivatives compounds. Sch. J. App. Med. Sci. 2013; 1(1): 20-27.
36. Siddiqui AA, Rahman MA, Shaharyar M and Mishra R. Synthesis And Anticonvulsant Activity Of Some Substituted 3,5-Diphenyl-2- Pyrazoline-1-Carboxamide Derivatives. CSJ. 2010: 1-10.
37. Enein MNA, Azzouny AAE, Attia MI, Maklad YA,Kamilia M. Amin KM, Rehim MA and Behairy MFE. Design and synthesis of novel stiripentol analogues as potential anticonvulsants. Eur J Med Chem. 2012; 47: 360- 369.
38. Cook AM, Bensalem-Owen MK. Mechanisms of action of antiepileptic drugs. Clinical Practice. 2011 May 1; 8(3):307.
39. Kobayashi K, Endoh F, Ohmori I, Akiyama T. Action of antiepileptic drugs on neurons. Brain and Development. 2020 Jan 1; 42(1):2-5.
40. Anwar H, Khan QU, Nadeem N, Pervaiz I, Ali M, Cheema FF. Epileptic seizures. Discoveries. 2020 Jun 12; 8(2):e110.
41. Francis F, Cappello S. Neuronal migration and disorders–an update. Current Opinion in Neurobiology. 2021 Feb 1; 66:57-68.
42. Dwivedi R, Kaushik M, Tripathi M, Dada R, Tiwari P. Unraveling the genetic basis of epilepsy: Recent advances and implications for diagnosis and treatment. Brain Research. 2024 Jul 18:149120.
43. Curia G, Lucchi C, Vinet J, Gualtieri F, Marinelli C, Torsello A, Costantino L, Biagini G. Pathophysiogenesis of mesial temporal lobe epilepsy: is prevention of damage antiepileptogenic? Current medicinal chemistry. 2014 Feb 1; 21(6):663-88.
44. Assal G, Majdalani A, Gautier JC. Epilepsie gelastique. Probable hamartome diencephalique. Rev Neurol 1993; 149:291–3.
45. Parvizi J, Le S, Foster BL, Bourgeois B, Riviello JJ, Prenger E, et al. Gelastic epilepsy and hypothalamic hamartomas: neuroanatomical analysis of brain lesions in 100 patients. Brain 2011; 134:2960–8.
46. Berkovic SF, Arzimanoglou A, Kuzniecky R, Harvey AS, Palmini A, Andermann F. Hypothalamic hamartoma and seizures: a treatable epileptic encephalopathy. Epilepsia 2003; 44:969–73.
47. Kovac S, Diehl B, Wehner T, et al. Gelastic seizures: incidence, clinical and EEG features in adult patients undergoing video-EEG telemetry. Epilepsia, 56: e1–e5. doi: http://dx.doi.org/10.1111/epi.12868
48. Fornari Caprara AL, Rissardo JP, Nagele EP. Rasmussen encephalitis: clinical features, pathophysiology, and management strategies—comprehensive literatures review. Medicina. 2024 Nov 12; 60(11):1858.
49. Oyrer J, Maljevic S, Scheffer IE, Berkovic SF, Petrou S, Reid CA. Ion channels in genetic epilepsy: from genes and mechanisms to disease-targeted therapies. Pharmacological reviews. 2018 Jan 1; 70(1):142-73.
50. Bryson A, Reid C, Petrou S. Fundamental neurochemistry review: GABA receptor neurotransmission and epilepsy: principles, disease mechanisms and pharmacotherapy. Journal of Neurochemistry. 2023 Apr; 165(1):6-28.
51. Meldrum BS. Excitatory amino acids in epilepsy and potential novel therapies. Epilepsy research. 1992 Jul 1; 12(2):189-96.
52. Patzke C, Brockmann MM, Dai J, Gan KJ, Grauel MK, Fenske P, Liu Y, Acuna C, Rosenmund C, Südhof TC. Neuromodulator signaling bidirectionally controls vesicle numbers in human synapses. Cell. 2019 Oct 3; 179(2):498-513.
53. Rao BM, Ramesh S, Bardalai D, Rahman H, Shaik HA. Synthesis, characterization and evaluation of anti-epileptic activity of four new 2-pyrazoline derivatives compounds. Sch. J. App. Med. Sci. 2013; 1(1):20-7.
54. Ahsan MJ, Ali A, Ali A, Thiriveedhi A, Bakht MA, Yusuf M, Salahuddin, Afzal O, Altamimi AS. Pyrazoline containing compounds as therapeutic targets for neurodegenerative disorders. ACS omega. 2022 Oct 17; 7(43):38207-45.
55. Sharma R, Verma A, Singh S. Antiepileptic activity of novel pyrazoline derivatives in experimental models. Int J Pharm Sci Res [Internet]. 2014 [cited 2025 Jul 9]; 5(8):3456–61.
56. Kumar A, Sharma R, Verma S. Evaluation of anti-inflammatory activity of herbal formulation in rats. Int J Pharm Sci Res. 2014; 5(3):1234–1239.
57. Patel NB, Jivani NP, Patel P. Synthesis and biological evaluation of some novel pyrazoline derivatives as potential anti-inflammatory agents. Med Chem Res. 2010; 19(9):948–956. Doi: 10.1007/s00044-009-9244-8.
58. Alam O, Naim MJ, Alam P, Sharaf A, Almohazey D, Almoshari Y, et al. Synthesis and anticonvulsant activity of novel 1,3,5-trisubstituted-2-pyrazolines. Med Chem Res. 2010; 19(10):1134–1144. Doi: 10.1007/s00044-009-9249-3.
59. Alam O, Naim MJ, Nawaz F, Alam P, Siddiqui NA. Synthesis and anticonvulsant activity of some novel 1, 3, 5-trisubstituted-2-pyrazolines. Med Chem Res. 2013; 22(6):2843–2851. Doi: 10.1007/s00044-012-0264-3
60. Kadi AA, Abdel-Hamid MK, Shehata IA, Al-Abdullah ES, Habib EE. Synthesis and anticonvulsant activity of new pyrazoline derivatives. Eur J Med Chem. 2010; 45(10):5006–5011. doi:10.1016/j.ejmech.2010.08.015
61. Alam O, Naim MJ, Alam P, Sharaf A, Almohazey D, Almoshari Y, Alharbi M, Aljasir MA, Altayb HN. Synthesis and anticonvulsant activity of novel 1, 3, 5-trisubstituted-2-pyrazolines. Med Chem Res. 2020; 29(3):469–478. Doi: 10.1007/s00044-019-02491-6
62. Kadi AA, Abdel-Hamid MK, Shehata IA, Al Abdullah ES, Habib EE. Synthesis and anticonvulsant activity of new pyrazoline derivatives including 1-(4-Bromophenyl)-3,5-diphenyl-2-pyrazoline. Med Chem Res. 2010; 19(10):1134–1144. Doi: 10.1007/s00044-009-9249-3.
63. Heifetz A, Mazanetz MP, James T, Pal S, Law RJ, Slack M, Biggin PC. From receptors to ligands: fragment-assisted drug design for GPCRs applied to the discovery of H3 and H4 receptor antagonists. Medicinal Chemistry. 2014; 4(1):322–329. doi:10.4172/2161-0444.1000158